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Abstract: Detailed analysis of the modular Type I polyketide
synthase (PKS) involved in the biosynthesis of the margino-
lactone azalomycin F in mangrove Streptomyces sp. 211726
has shown that only nineteen extension modules are required to
accomplish twenty cycles of polyketide chain elongation.
Analysis of the products of a PKS mutant specifically
inactivated in the dehydratase domain of extension-module
1 showed that this module catalyzes two successive elongations
with different outcomes. Strikingly, the enoylreductase domain
of this module can apparently be “toggled” off and on : it
functions in only the second of these two cycles. This novel
mechanism expands our understanding of PKS assembly-line
catalysis and may explain examples of apparent non-colinear-
ity in other modular PKS systems.
Modular Type I polyketide synthases (PKSs) catalyze the
biosynthesis of numerous pharmacologically relevant natural
products that exhibit antibacterial, antifungal, anthelmintic,
antitumor, or immunosuppressive activities.[1–4] These giant
multimodular enzymes form a processive assembly-line to
produce the polyketide backbone using (alkyl)malonyl-CoA
esters as the source of extender units. Each module consists of
a b-ketoacyl synthase (KS) domain for condensing the
incoming unit onto the growing polyketide chain, an acyl-
transferase (AT) domain for loading extension units, and an
acyl carrier protein (ACP) domain for retention of the
growing polyketide chain on the PKS. In addition to these
conserved domains, b-ketoreductase (KR), dehydratase
(DH), and enoylreductase (ER) domains are optional to
achieve varying degrees of reduction. Finally, the full-length
chain is released, for example by a cyclase/thioesterase
(TE).[5] In general, the organization of modules and domains
corresponds exactly to the chemical structure of the initial
polyketide product. This colinear property has made modular
PKSs attractive subjects for rational bioengineering to
produce novel bioactive compounds,[6] and has facilitated
the “mining” of genome sequences for novel biosynthetic
pathways.[7–9]However, there is growing interest in exceptions
to this rule. An early example is the pikromycin PKS, which
produces both a 12-membered and a 14-membered macrolide
through optional “skipping”[10] of a PKS module. In other
examples, a single extension module catalyzes two or more
successive (and identical) rounds of polyketide carbon
skeleton, either to give aberrant products[11] or as part of
the normal biosynthetic pathway.[12–16] These exceptions
promise to increase our understanding of the natural evolu-
tion of modular PKSs, and potentially offer lessons for the
effective engineering of these systems.
The 36-membered macrocyclic antifungal azalomycins
(AZLs) are the main products of Streptomyces sp. 211726,
which has been isolated from mangrove rhizosphere soil.[17,18]
These compounds show broad-spectrum antimicrobial activ-
ity, and cytotoxicity against a human colon tumor cell
line.[17, 18] Azalomycin F5a and certain F5a derivatives also
show anti-MRSA activity.[19] Azalomycins F3a, F4a, and F5a
are also produced by Streptomyces malaysiensisDSM 4137,[20]
and we have previously proposed a model in which the first
extension module catalyzes both the first and second cycles of
polyketide chain extension, based on the observation that
when the cluster is transplanted into a heterologous strain,
azalomycins are produced, which rules out the participation
of an additional PKS encoded elsewhere in the S. malaysiensis
genome.[21] Whole-genome sequencing of Streptomyces sp.
211726 revealed a cluster (GenBank accession number:
KY484834) that is highly similar, both in size and organiza-
tion, to the azalomycin cluster in DSM 4137.[20] It has exactly
the same module and domain arrangement and flanking
auxiliary genes spanning an approximately 130 kb region of
DNA (Figure 1 and Table S1 in the Supporting Information),
and deletion of the entire region (Figure S1 in the Supporting
Information) led to total loss of AZL production. As before,
the loss of colinearity is readily localized to modules 1 and 2
(Figure 2 and Figure S2).
In order to test the hypothesis that extension-module 1
acts iteratively and supplies the missing full reduction module
governing the second extension, a site-specific mutation of the
essential histidine residue to alanine was introduced into the
active site of the DH1 domain in vivo (Figure S3). Liquid
chromatography electrospray ionization high-resolution mass
spectrometry (LC-ESI-HRMS) analysis showed that the
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DDH1 mutant strain no longer produces known AZLs, and
instead significant new peaks were found (Figure 3c and
Figure S4), albeit at levels only 0.1% of AZL levels in the
wild-type. Analysis of these new peaks revealed compounds
closely related to azalomycins F3a, F4a, and F5a, except that
they bear hydroxy groups at C-41 and C-39, instead of
a double bond between C-40 and C-41 (Figure 3c and
Figure S4). These compounds, named F3a’, F4a’, and F5a’,
were isolated from a large-scale fermentation, and their
structures were elucidated by 1H NMR and DEPT spectros-
copy. The NMR data showed in each case the loss of two
olefinic protons (dH 5.38–5.46, 2H) and the presence of two
additional O-bound protons at dH 3.65 and dH 4.04 (Figure S5)
compared to the known azalomycins. In agreement with this,
the DEPT analysis showed a lack of two
olefinic carbon atoms at dC 128.9 and dC
131.0 Figure S6). Clearly, inactivation of
the DH1 domain prevents dehydration in
both the first and second extensions, thus
providing direct evidence that in the AZL
PKS, module 1 is used twice.
The PKS AzlA houses only the load-
ing module (LM) and extension-module 1.
To further confirm the above result by
in vitro analysis, the recombinant PKS
AzlA(DDH1), which bears the same site-
directed mutation in the DH1 domain as
above, was successfully expressed in solu-
ble form in Escherichia coli BAP1[22] with
post-translational modification of the
ACP1 domain. In a one-pot reaction with
4-guanidinobutyric acid, purified Azl4 (ligase), Azl5 (acyl-
transferase), and AzlA(DDH1), the starter unit 4-guanidino-
butyryl-CoA was produced and loaded onto the ACPL
domain that comprises the LM in AzlA(DDH1). In order to
achieve multiple turnovers of polyketide synthesis on the
AzlA PKS multienzyme, our strategy[23] was to supply addi-
tional copies of the ACP1 domain. Recombinant holo-ACP1
domain was expressed as a stand-alone protein and purified
from E. coli BAP1 and added to the incubations to compete
with the integral ACP1 domain of module 1 (Figure S7). The
polyketide-chain-bearing ACP1 reaction products were moni-
tored by LC-ESI-HRMS. In the presence of holo-ACP1 and
malonyl-CoA in the above one-pot reaction, a peak with
a mass corresponding to the expected product of two rounds
Figure 2. Non-colinearity between the AZL PKS assembly line and the product structure. a) Proposed
chemical structure of AZL (the guanidino-substituted chain is shown) deduced from the nucleotide
sequence and the predicted domain organization of the AZL biosynthetic gene cluster. b) Bioinformatic
prediction of PKS organization based on the actual structure of AZL according to the canonical
colinearity rule.
Figure 1. a) Organization of the azalomycin F biosynthetic gene cluster. The PKS-encoding genes are highlighted in gray. b) Structures of
azalomycin F analogues. Bold lines indicate the malonyl and methylmalonyl extender units incorporated by each acyltransferase domain of the
PKS. Compounds 4–12 are minor components.
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of extension (8-guanidino-3,5-dihydroxyoctanoyl-ACP1) was
observed (Figure 3d). A further peak was detected corre-
sponding to the mass of 6-guanidino-3-hydroxyhexanoyl-
ACP1, the expected product of a single cycle of chain
extension (Figure 3d). To confirm these findings, thioester-
bound products were hydrolyzed with potassium hydroxide as
described[24] in both assays with and without holo-ACP1 and
showed the same result. LC-ESI-HRMS analysis of the
hydrolyzed products revealed two peaks, corresponding to
6-guanidino-3-hydroxyhexanoic acid and 8-guanidino-3,5-
dihydroxyoctanoic acid, respectively, which is in agreement
with the analysis of the acyl-ACP1 species (Figure 3e). Taken
together, these results demonstrate conclusively that the AZL
PKS extension-module 1 catalyzes two successive cycles of
chain extension. In the iterative mechanism we propose for
the intact AZL PKS (Figure S7), after the first round of
extension, the ACP1-tethered polyketide intermediate is
transferred back to the KS1 domain on the opposite PKS
strand[25] instead of the downstream KS2 domain, probably
owing to the preference of KS2 for the triketide acyl-ACP as
a substrate over the diketide acyl-ACP.
Notably, only one full reduction occurs during the first two
extension cycles on the AZL PKS. To investigate the behavior
of the ER1 domain in module 1, the same experimental
approach as above, in which recombinant ACP1 was used in
a one-pot reaction with
wild-type AzlA (Fig-
ure S7), was used. Since
module 1 contains a full
set of reductive enzyme
domains (DH, ER, KR),
and recruits malonyl-
CoA as extender unit,
the 4-guanidinobutyryl
starter unit should be
extended with two ace-
tate units and both newly-
formed b-keto groups
should be fully reduced.
However, LC-ESI-
HRMS analysis of the
one-pot reaction showed
that the molecular weight
of the acyl-ACP1 species
produced was 2 Da less
than expected for the
product of two rounds
with full reduction (Fig-
ure 3d), thus suggesting
incomplete reduction in
one cycle. To confirm
this, analysis of the acyl
chain after its release
from ACP1 by alkaline
hydrolysis showed it to
be 8-guanidinooct-4-
enoic acid (Figure 3e).
Therefore, AzlA cata-
lyzes two elongations, in
only one of which the enoylreductase (ER) domain acts. The
position of the double bond in all natural AZL compounds
(between C-40 and C-41) is fully consistent with ER1 being
inactive in the first extension but active in the second one.
The programmed iteration of extension-module 1 on the
AZL PKS occurs, as with previously identified examples of
programmed iteration of modules,[11,26] at a point in the
assembly line where there is a protein–protein interface[27]
(here between AzlA and AzlB). Those previous examples all
involve the same level of b-keto processing in each of the
iterative rounds of chain elongation. Here, we report an
unprecedented example in which every domain except the
ER is used during two successive rounds of elongation, while
the ER domain is non-functional (“off”) in the first but
functional (“on”) in the second extension process. Never-
theless, the iterative use of module 1 and the ER1 skipping
event in the first extension can both be accounted for in terms
of kinetic control: the intrinsic selectivity of the ER1 domain,
which discriminates against the shorter substrate, would favor
back-transfer of the acyl chain onto KS1. Likewise, for the KS1
active site to be re-used, the back-transfer must outcompete
the priming of KS1 through transfer of the 4-guanidinobutyryl
starter unit from the adjacent ACPL loading domain. After
two rounds of extension, the partitioning of the triketide acyl-
ACP intermediate favors full reduction rather than transfer to
Figure 3. A model for the toggling ER1 domain in iterative-module 1 based on the results of inactivation of the
DH1 domain in vivo and in vitro. a) Domain organization of AzlA. Module 1 is used twice, and the toggling ER1
domain is programmed to be inactive (shaded in black) in the first extension but active in the second extension.
b) Domain organization of AzlA(DDH1). The DH1 domain marked with a cross was inactivated by site-specific
mutagenesis in the 211726 chromosome and the AzlA recombinant multienzyme. c) LC-ESI-HRMS analysis of
fermentation products from wild-type 211726 and the DDH1 mutant. Only F4a and its derivative F4b, the main
products of AZL, are shown. d) LC-ESI-HRMS protein analysis of an in vitro reconstitution assay of AzlA and
AzlA(DDH1) with added recombinant stand-alone ACP1. e) LC-ESI-HRMS analysis of the same in vitro assay
mixture as in (d) except that the reaction mixture was subjected to alkaline hydrolysis before analysis. The three
traces are presented on the same scale.
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the next module. The downstream KS2 domain on the
adjacent PKS subunit AzlB may well act as a “gatekeeper”,
favoring selective recruitment of a triketide- rather than
a diketide-acyl chain. Evidence from a study of the aureothin
PKS[28] strongly supports such an interplay of multiple factors
in programmed iteration.
Selective processing during two successive iterations of
polyketide chain extension is a known feature in highly
reducing fully iterative polyketide synthases.[29–31] In the LovB
PKS, for example, which synthesizes the nonaketide core of
the cholesterol-lowering compound lovastatin using a single
PKS module, an integral methyltransferase domain selec-
tively methylates the b-ketothioester formed after three
rounds of chain extension.[29] In vitro analysis of model
thioester substrates for LovB has demonstrated that the
methyltransferase is exquisitely specific for the tetraketide
substrate, and that for this substrate, methylation effectively
outcompetes prior ketoreduction.[32] LovB also recruits an
exogenous monomeric ER protein (LovC) to catalyze specific
enoyl reduction in only three out of the eight extension cycles
(tetra-, penta-, and heptaketide intermediates).[32] Detailed
analysis of LovC has suggested that while the competent
substrates are readily accommodated in a productive con-
formation, shorter intermediates preferentially adopt non-
productive conformations in the active site.[32] Meanwhile, the
hexaketide intermediate preferentially undergoes Diels–
Alder-like cyclization. Similar experiments will be needed
to establish the precise structural basis for the remarkable
switch that flips the AzlA ER1 domain from “off” to “on”
during azalomycin biosynthesis.
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